Evidence map›Paper›PMID 41644530›Full record

ArticleNature communications2026

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

Divya Lenkala, Jessica Kohler, Brian McCarthy, Michael Nelson, Noor A M Bakker, Renate de Boer, Emily K Jackson, Joong Hyuk F Sheen, Susan Hannes, Ekaterina Esaulova and 29 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Divya LenkalaBioNTech US, Cambridge, MA, USA.
Jessica KohlerBioNTech US, Cambridge, MA, USA.
Brian McCarthyBioNTech US, Cambridge, MA, USA.
Michael NelsonBioNTech US, Cambridge, MA, USA.
Noor A M BakkerNetherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-7167-581X
Renate de BoerNetherlands Cancer Institute, Amsterdam, The Netherlands.
Emily K JacksonBioNTech US, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2972-4139
Joong Hyuk F SheenBioNTech US, Cambridge, MA, USA.
Susan HannesBioNTech US, Cambridge, MA, USA.
Ekaterina EsaulovaBioNTech US, Cambridge, MA, USA.
Kai StewartBioNTech US, Cambridge, MA, USA.
Claudia GottsteinBioNTech SE, Mainz, Germany.ORCID http://orcid.org/0009-0008-1117-8417
John AttanasioBioNTech US, Cambridge, MA, USA.
Flavian D BrownBioNTech US, Cambridge, MA, USA.
Sebastian HymsonBioNTech US, Cambridge, MA, USA.ORCID http://orcid.org/0009-0001-1823-9680
Shirisha MedaBioNTech US, Cambridge, MA, USA.
Maaike van ZonNetherlands Cancer Institute, Amsterdam, The Netherlands.
Saskia ScheijNetherlands Cancer Institute, Amsterdam, The Netherlands.
Rhianne VoogdNetherlands Cancer Institute, Amsterdam, The Netherlands.
Brenda RaudNetherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1416-0529
Ziyan XuBioNTech US, Cambridge, MA, USA.
Jessica S W BorgersNetherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-6478-7821
Maartje W RohaanNetherlands Cancer Institute, Amsterdam, The Netherlands.
Kristen N BaloghBioNTech US, Cambridge, MA, USA.
Asaf PoranBioNTech US, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9118-1051
Michael RooneyBioNTech US, Cambridge, MA, USA.
Jesse Z DongBioNTech US, Cambridge, MA, USA.
John R SroujiBioNTech US, Cambridge, MA, USA.
Vikram R JunejaBioNTech US, Cambridge, MA, USA.
Christina M ArietaBioNTech US, Cambridge, MA, USA.
Cynthia M NijenhuisNetherlands Cancer Institute, Amsterdam, The Netherlands.
Bastiaan NuijenNetherlands Cancer Institute, Amsterdam, The Netherlands.
Mark DeMarioBioNTech US, Cambridge, MA, USA.
Kelledy MansonBioNTech US, Cambridge, MA, USA.
Ton N M SchumacherNetherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-0517-8804
Richard B GaynorBioNTech US, Cambridge, MA, USA.
John B HaanenNetherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-5884-7704
Joost H van den BergNetherlands Cancer Institute, Amsterdam, The Netherlands.
Marit M van BuurenBioNTech US, Cambridge, MA, USA. Marit.vanBuuren@biontech.us.ORCID http://orcid.org/0000-0002-1615-1087

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoantigen-based adoptive T cell therapies (ACTs) represent a promising avenue in cancer immunotherapy due to their exquisite tumor specificity. The first cell-based immunotherapy for a solid tumor, comprising tumor-infiltrating lymphocytes, recently received FDA approval. Building on this, we designed a distinct ACT approach, where T cell responses against personalized neoantigens are systematically generated from autologous peripheral blood. Here we report the establishment of NEO-STIM, an ex vivo induction process to prime and expand pre-existing memory and de novo CD8

Indexed as

Antigens, NeoplasmImmunotherapy, AdoptiveNeoplasmsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHumansLymphocytes, Tumor-InfiltratingPrecision MedicineAntigens, Neoplasm

Identifiers

PMID41644530
PMCPMC13099984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.